Bevyxxa is a potent and specific inhibitor of human factor Xa activity that acts by competitively binding to the active site of factor Xa, preventing its ability to convert prothrombin to thrombin. It is the first non-vitamin K antagonist oral anticoagulant (NOAC) approved by the FDA for venous thromboembolism (VTE) prophylaxis in hospitalized acute medically ill adult patients who are at risk for thromboembolic complications.
If you have a Hayes login, click here to view the full report on the Knowledge Center.